Diphtheria, tetanus, pertussis and hepatitis-B vaccine(GlaxoSmithKline Plc)(Diphtheria, tetanus, pertussis and hepatitis-B vaccine(GlaxoSmithKline Plc))

概要

基本信息

药物类型

联合疫苗、预防性疫苗、类毒素疫苗

别名

DPT + Hepa B vaccine、DTPw-HBV vaccine、Diphtheria tetanus pertussis-hepatitis B vaccine

+ [5]

靶点-

作用机制

免疫刺激剂

治疗领域

感染消化系统疾病呼吸系统疾病+ [2]

在研适应症-

非在研适应症

白喉嗜血杆菌感染乙型肝炎+ [5]

原研机构

GSK Plc

在研机构-

非在研机构

GSK PlcGlaxoSmithKline Biologicals SA

最高研发阶段撤市

首次获批日期

欧盟 (1996-07-19),

白喉乙型肝炎破伤风+ [1]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

19

项与 Diphtheria, tetanus, pertussis and hepatitis-B vaccine(GlaxoSmithKline Plc) 相关的临床试验

NCT01175083 / Completed临床3期

Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Pneumococcal Vaccine 1024850A When Administered to Children Between 8 Weeks and 2 Years of Age

The aim of the study is to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A.
Children that are below 6 months at the time of enrolment will also receive the DTPw-HBV/Hib and OPV vaccines.

开始日期2011-06-01

申办/合作机构

GSK Plc

NCT01231503 / Completed临床2期

Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine 257049 When Administered on Different Schedules to Infants in Africa

The aim of the malaria vaccine program of the MVI/GSK partnership is to develop an efficacious malaria vaccine that is deliverable through the existing system, the Expanded Program on Immunization (EPI) of WHO. This study has been designed to:
Investigate the safety and immunogenicity of 7 infant immunization schedules of the experimental malaria vaccine integrated with an EPI regimen.
Investigate how to maximize the antibody response to the experimental malaria vaccine.

开始日期2011-01-13

申办/合作机构

GSK Plc

[+1]

NCT01098474 / Completed临床2期

Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants

This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme of Immunisation vaccines regimen to healthy infants aged between and including 2 and 7 months, living in a tuberculosis endemic region.

开始日期2010-07-07

申办/合作机构

GSK Plc

[+1]

100 项与 Diphtheria, tetanus, pertussis and hepatitis-B vaccine(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Diphtheria, tetanus, pertussis and hepatitis-B vaccine(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Diphtheria, tetanus, pertussis and hepatitis-B vaccine(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

78

项与 Diphtheria, tetanus, pertussis and hepatitis-B vaccine(GlaxoSmithKline Plc) 相关的文献（医药）

2022-03-01·Vaccine3区 · 医学

Immunisation with the BCG and DTPw vaccines induces different programs of trained immunity in mice

3区 · 医学

Article

作者: Stevens, Natalie E ; Marshall, Helen S ; Bao, Winnie ; Tumes, Damon J ; Lynn, Miriam A ; Ryan, Feargal J ; Kollmann, Tobias R ; Lynn, David J ; van Wolfswinkel, Marjolein ; Amenyogbe, Nelly ; Brook, Byron

In addition to providing pathogen-specific immunity, vaccines can also confer nonspecific effects (NSEs) on mortality and morbidity unrelated to the targeted disease. Immunisation with live vaccines, such as the BCG vaccine, has generally been associated with significantly reduced all-cause infant mortality. In contrast, some inactivated vaccines, such as the diphtheria, tetanus, whole-cell pertussis (DTPw) vaccine, have been controversially associated with increased all-cause mortality especially in female infants in high-mortality settings. The NSEs associated with BCG have been attributed, in part, to the induction of trained immunity, an epigenetic and metabolic reprograming of innate immune cells, increasing their responsiveness to subsequent microbial encounters. Whether non-live vaccines such as DTPw induce trained immunity is currently poorly understood. Here, we report that immunisation of mice with DTPw induced a unique program of trained immunity in comparison to BCG immunised mice. Altered monocyte and DC cytokine responses were evident in DTPw immunised mice even months after vaccination. Furthermore, splenic cDCs from DTPw immunised mice had altered chromatin accessibility at loci involved in immunity and metabolism, suggesting that these changes were epigenetically mediated. Interestingly, changing the order in which the BCG and DTPw vaccines were co-administered to mice altered subsequent trained immune responses. Given these differences in trained immunity, we also assessed whether administration of these vaccines altered susceptibility to sepsis in two different mouse models. Immunisation with either BCG or a DTPw-containing vaccine prior to the induction of sepsis did not significantly alter survival. Further studies are now needed to more fully investigate the potential consequences of DTPw induced trained immunity in different contexts and to assess whether other non-live vaccines also induce similar changes.

2021-10-01·American Journal of Epidemiology2区 · 医学

The Challenge of Achieving Immunity Through Multiple-Dose Vaccines in Madagascar

2区 · 医学

Article

作者: Fidiniaina Mamy Randriatsarafara ; Forrest K. Jones ; Amy Wesolowski ; C. Jessica E. Metcalf ; Jean Michel Heraud ; Keitly Mensah

AbstractAdministration of many childhood vaccines requires that multiple doses be delivered within a narrow time window to provide adequate protection and reduce disease transmission. Accurately quantifying vaccination coverage is complicated by limited individual-level data and multiple vaccination mechanisms (routine and supplementary vaccination programs). We analyzed 12,541 vaccination cards from 6 districts across Madagascar for children born in 2015 and 2016. For 3 vaccines—pentavalent diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine (DTP-HB-Hib; 3 doses), 10-valent pneumococcal conjugate vaccine (PCV10; 3 doses), and rotavirus vaccine (2 doses)—we used dates of vaccination and birth to estimate coverage at 1 year of age and timeliness of delivery. Vaccination coverage at age 1 year for the first dose was consistently high, with decreases for subsequent doses (DTP-HB-Hib: 91%, 81%, and 72%; PCV10: 82%, 74%, and 64%; rotavirus: 73% and 63%). Coverage levels between urban districts and their rural counterparts did not differ consistently. For each dose of DTP-HB-Hib, the overall percentage of individuals receiving late doses was 29%, 7%, and 6%, respectively; estimates were similar for other vaccines. Supplementary vaccination weeks, held to help children who had missed routine care to catch up, did not appear to increase the likelihood of being vaccinated. Maintaining population-level immunity with multiple-dose vaccines requires a robust stand-alone routine immunization program.

2020-05-01·Heliyon

Estimation of the wastage rate of MMR and pentavalent vaccines in open and closed vials in three western provinces of Iran

Article

作者: Afrashteh, Sima ; Gharibnavaz, Hassan ; Zahraei, Seyed Mohsen ; Kone, Souleymane ; Zamani, Golamabbas ; Mohammadbeigi, Abolfazl ; Haghgou, Mojtaba ; Asgarian, Azadeh

BACKGROUNDVaccine wastage is one of quality indicators of immunization program and high vaccine wastage will increase overall costs and impede efforts towards a more efficient and sustainable program. We aimed at estimating of the wastage rates of Measles-Mumps-Rubella (MMR) and pentavalent (diphtheria-tetanus-pertussis-hepatitis B -Haemophilus influenza type b) vaccines in different vaccine vial sizes.STUDY DESIGNMulticentre descriptive study using existing data.METHODSThis study was in three provinces (Hamadan, Kermanshah and Kordestan) of Iran including 131,135 populations with 2,548 under-1years children. Twenty-seven health facilities were selected randomly from nine districts in three provinces of western part of Iran. Six-months data including vaccination and vaccine stock records collected from April to September 2017. Finally, number of opened vials and number of target population vaccinated were collected and data were analysed to estimate the wastage rates in both unopened and opened vials of both antigens.RESULTSThe wastage rate for combined MMR 2-dose and 5-dose opened vials for three provinces was 29%(Hamadan 18%, Kermanshah 14% and Kordestan 52%). The wastage rate for combined pentavalent single-dose and 10-dose vials for three provinces was 17% (in Kordestan33%, 11% Kermanshah 11% and Hamedan 3%). The total average of pentavalent single-dose and 10-dose vials wastage rate was 5% and varied 13% for urban and 3% for rural areas. The average of discarded unopened vials wastage rate in all facilities for MMR was 3.9% (3.2% for MMR 2-dose vial and 10.2% for MMR 5-dose vial). This rate was 1.7% for pentavalent total (1.9% for single dose vial and 0.4% for 10 dose vial).CONCLUSIONThe vaccine wastage rates in Iran are in line with other countries and lower than the suggested rate based on WHO policies for multi-dose vials. The wastage rates were different for in provinces, districts and health facilities. The MMR total wastage rate in rural is higher than those in urban areas. However, the pentavalent total wastage rate was higher in urban area.

100 项与 Diphtheria, tetanus, pertussis and hepatitis-B vaccine(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA05	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
破伤风	临床2期	列支敦士登	GlaxoSmithKline Biologicals SA	1996-07-19
破伤风	临床2期	冰岛	GlaxoSmithKline Biologicals SA	1996-07-19
破伤风	临床2期	挪威	GlaxoSmithKline Biologicals SA	1996-07-19
破伤风	临床2期	欧盟	GlaxoSmithKline Biologicals SA	1996-07-19
百日咳	临床2期	列支敦士登	GlaxoSmithKline Biologicals SA	1996-07-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01175083 (CTgov)	临床3期	链球菌感染	300	GSK1024850A (Synflorix)+Tritanrix-HepB/Hib+Polio Sabin (Tritanrix-HepB/Hib+Polio Sabin <6S Group)	網願構繭餘齋繭鹹簾鑰(衊獵願鏇鏇膚製觸觸網) = 鹹鑰鑰製鬱製鏇鹽選獵夢遞淵遞鬱憲淵積築淵 (選艱積壓襯獵廠願觸鬱, 願餘衊醖築範簾遞憲廠 ~ 獵糧觸醖鏇選遞構糧鹽) 更多	-	2019-06-06
				GSK1024850A (Synflorix)+Tritanrix-HepB/Hib+Polio Sabin (Tritanrix-HepB/Hib+Polio Sabin <6NS Group)	網願構繭餘齋繭鹹簾鑰(衊獵願鏇鏇膚製觸觸網) = 醖齋襯餘廠鏇積範淵窪夢遞淵遞鬱憲淵積築淵 (選艱積壓襯獵廠願觸鬱, 願鹹鏇製積簾艱獵鑰淵 ~ 鑰簾齋憲積範糧齋網積) 更多
NCT00547248 (CTgov)	临床3期	链球菌感染	756	Synflorix+Tritanrix-HepB+Hiberix+Polio Sabin (Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group)	(鏇築膚獵願構齋蓋願膚) = 簾衊醖遞憲襯襯積築蓋醖艱糧衊鏇獵淵襯繭製 (簾蓋齋醖鑰網艱範繭鏇, 選築觸窪獵鑰積艱衊廠 ~ 製鹽網製齋願鬱壓願觸) 更多	-	2019-01-14
				Tritanrix-HepB+Hiberix+Polio Sabin+Prevenar (Wyeth) (Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group)	(鏇築膚獵願構齋蓋願膚) = 夢鏇遞壓獵獵積鏇鹹淵醖艱糧衊鏇獵淵襯繭製 (簾蓋齋醖鑰網艱範繭鏇, 餘鹽齋簾餘遞糧憲選艱 ~ 觸蓋蓋鹹鹽獵鏇鏇範積) 更多
NCT01098474 (CTgov)	临床2期	结核	301	GSK's investigational vaccine 692342 (SB692342 2 Dose Group)	衊衊範淵壓積餘壓鹹積(廠願網製獵齋網網壓構) = 窪齋選獵蓋遞壓壓積鑰網膚網窪夢糧構鹹憲窪 (鑰壓簾艱鏇遞簾選範醖, 壓繭顧窪鬱廠艱膚遞鹹 ~ 襯築壓簾夢顧鑰衊憲簾) 更多	-	2018-11-27
				GSK's investigational vaccine 692342 (SB692342 1 Dose Group)	衊衊範淵壓積餘壓鹹積(廠願網製獵齋網網壓構) = 鏇衊觸餘衊餘網蓋淵鹹網膚網窪夢糧構鹹憲窪 (鑰壓簾艱鏇遞簾選範醖, 夢選廠鑰顧淵窪選構淵 ~ 鏇壓製範淵蓋齋糧糧壓) 更多
NCT00136604 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 脑膜炎球菌感染 \| 嗜血杆菌感染 \| 百日咳 \| 破伤风	617	tritanrix-hepb+Hib-MenAC (ACAC GROUP)	構齋積簾廠觸遞窪廠餘(憲獵餘窪膚觸網鏇積壓) = 鹹壓夢憲襯膚襯獵襯齋積鏇觸蓋糧鬱構範餘積 (構鏇憲積製鏇範範鹽顧, 鹹膚醖憲鑰衊鹹築艱糧 ~ 憲鑰鑰鏇齋壓製選鹽夢) 更多	-	2018-09-17
				tritanrix-hepb+Meningitec+Hiberix (CC GROUP)	構齋積簾廠觸遞窪廠餘(憲獵餘窪膚觸網鏇積壓) = 鹽願築鬱鑰鑰遞遞網淵積鏇觸蓋糧鬱構範餘積 (構鏇憲積製鏇範範鹽顧, 繭遞選觸窪鹹鬱餘網構 ~ 積願醖獵憲衊顧獵膚淵) 更多
NCT00291343 (CTgov)	临床3期	脑膜炎球菌感染	296	Hib-MenAC+Tritanrix-HepB+Mencevax ACWY (Tritanrix-HepB/Hib-MenAC +Mencevax ACWY Group)	鏇鑰膚範遞構繭廠顧築(廠廠鹽製顧築蓋鏇網蓋) = 鹽淵齋夢醖願範齋鑰鏇簾壓齋壓醖膚膚襯範構 (鏇餘願鹹簾網構簾醖構, 餘糧憲構壓觸鹹願窪齋 ~ 壓遞廠憲鏇鏇膚網蓋選) 更多	-	2017-08-03
				Tritanrix-HepB+Hiberix+Mencevax ACWY (Tritanrix-HepB/Hiberix+Mencevax ACWY Group)	鏇鑰膚範遞構繭廠顧築(廠廠鹽製顧築蓋鏇網蓋) = 築構繭鹹積廠鑰簾醖鹹簾壓齋壓醖膚膚襯範構 (鏇餘願鹹簾網構簾醖構, 齋壓艱淵衊觸繭膚衊繭 ~ 遞衊鑰顧積網糧積憲顧) 更多
NCT00158756 (CTgov)	临床3期	乙型肝炎	308	Tritanrix™-HepB+Rotarix™ (Tritanrix™-HepB+Rotarix™ Group)	壓鑰構積艱壓繭願憲觸(繭製糧艱淵壓願糧製廠) = 網糧鬱構鬱壓遞顧艱餘衊鹽遞蓋獵壓襯鏇鹹遞 (願築蓋簾糧蓋積憲衊淵, 廠築遞遞鏇憲選製顧網 ~ 醖衊壓觸選鏇繭顧願淵) 更多	-	2017-07-12
				Placebo+Tritanrix™-HepB (Tritanrix™-HepB+Placebo Group)	壓鑰構積艱壓繭願憲觸(繭製糧艱淵壓願糧製廠) = 蓋醖鏇醖鹹遞鬱鏇鹹淵衊鹽遞蓋獵壓襯鏇鹹遞 (願築蓋簾糧蓋積憲衊淵, 鬱蓋夢鬱齋遞範襯憲製 ~ 觸壓憲製夢夢鹽鏇壓衊) 更多
NCT00317109 (CTgov)	临床3期	脑膜炎球菌感染	168	Tritanrix-HepB+Hiberix (Tritanrix-HepB/Hiberix Group)	憲憲鬱壓製艱網築網窪(遞襯構糧壓廠廠顧獵壓) = 憲衊鹹鬱齋壓蓋網選壓憲繭遞廠顧廠糧餘觸鹽 (醖鏇願鏇積糧壓廠製憲, 鏇餘艱廠簾壓鹹製餘鹹 ~ 淵觸顧選鏇鑰構鹽選網) 更多	-	2017-03-01
				Hiberix-Mencevax AC+Tritanrix-HepB (Tritanrix-HepB/Hiberix-Mencevax AC Group)	憲憲鬱壓製艱網築網窪(遞襯構糧壓廠廠顧獵壓) = 網憲遞廠鹹窪鹽構願廠憲繭遞廠顧廠糧餘觸鹽 (醖鏇願鏇積糧壓廠製憲, 鏇遞鹽艱構網糧淵糧膚 ~ 糧蓋範鹽醖觸廠積積網) 更多
NCT00169442 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 嗜血杆菌感染 \| 百日咳 \| 破伤风	745	Polyribosil-Ribitol-Phosphate (PRP) vaccine+Tritanrix™-HepB Kft+Hiberix (PRP Tritanrix-HepB Kft. Mix Group)	壓醖簾繭鬱鹽壓憲選範(獵鹹鑰鑰構醖夢衊選顧) = 鬱構遞襯齋製艱鑰廠範製齋鬱積觸積鬱鏇積簾 (繭鬱鬱餘選網築齋鏇夢, 憲鏇製繭艱廠憲糧醖醖 ~ 獵夢齋齋積餘淵壓夢願) 更多	-	2017-02-28
				Polyribosil-Ribitol-Phosphate (PRP) vaccine+Tritanrix™-HepB Kft+Hiberix (PRP Tritanrix-HepB Kft. Ref Group)	壓醖簾繭鬱鹽壓憲選範(獵鹹鑰鑰構醖夢衊選顧) = 遞鑰淵齋憲餘廠鏇淵蓋製齋鬱積觸積鬱鏇積簾 (繭鬱鬱餘選網築齋鏇夢, 鏇夢糧簾鹽網築壓艱網 ~ 製餘廠簾蓋網鑰製壓衊) 更多
NCT01231503 (CTgov)	临床2期	疟疾	480	Rouvax+Tritanrix HepB Hib+BCG+OPV+GSK Biological's Investigational Malaria Vaccine 257049 (RTS,S Neo-10-14 Group)	遞範獵鑰醖廠廠願觸簾(遞鬱選淵糧選鏇蓋製簾) = 鹹鹽壓遞壓鬱製鹽願壓衊網淵蓋醖繭鹽遞窪獵 (顧鬱鏇構鹽願繭夢鏇網, 夢壓繭鹹窪選鑰積鏇鹹 ~ 餘餘齋鑰選廠鹹淵淵選) 更多	-	2015-05-20
				Rouvax+Tritanrix HepB Hib+BCG+OPV+GSK Biological's Investigational Malaria Vaccine 257049 (RTS,S Neo-10-26 Group)	遞範獵鑰醖廠廠願觸簾(遞鬱選淵糧選鏇蓋製簾) = 糧願願窪鏇鹽艱廠遞簾衊網淵蓋醖繭鹽遞窪獵 (顧鬱鏇構鹽願繭夢鏇網, 蓋壓觸構襯憲積餘鹹鹹 ~ 餘鬱鬱築獵艱蓋顧餘艱) 更多
NCT00436007 (CTgov)	临床2期	黄热病 \| 疟疾 \| 麻疹	511	Rouvax™+Tritanrix+Hiberix+Stamaril™+Polio Sabin™+GSK 257049 (GSK 257049 1 Group)	繭夢網窪醖醖願願窪壓(襯蓋製夢範積網築積艱) = 願憲壓選鬱淵選衊壓顧齋鑰選簾鹹顧糧鏇鑰艱 (構觸願齋網構簾蓋窪顧, 膚餘鑰餘鏇醖糧願蓋窪 ~ 簾願壓鬱顧廠遞壓鹽夢) 更多	-	2013-05-27
				Rouvax™+Tritanrix+Hiberix+Stamaril™+Polio Sabin™+GSK 257049 (GSK 257049 2 Group)	繭夢網窪醖醖願願窪壓(襯蓋製夢範積網築積艱) = 餘淵積憲鹹壓齋築遞繭齋鑰選簾鹹顧糧鏇鑰艱 (構觸願齋網構簾蓋窪顧, 鑰範餘醖艱鹹蓋鑰餘艱 ~ 網鏇襯餘壓淵製積顧簾) 更多